Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. An estimated 6.2 million people are infected every year, including over 4.5 million young people between 15 and 24 years of age. In June 2006, the first vaccine to prevent HPV strains 6, 11, 16, and 18 was licensed by the U.S. Food and Drug Administration (FDA) for use among females 9 to 26 years of age. Although most infections clear naturally, persistent infection with these strains of HPV are causally associated with about 90% of genital warts and up to 70% of all cervical cancers. The licensed vaccine, Gardasil™, is administered in a series of three injections over a six-month period and targets the four previously mentioned HPV types most commonly associated with genital warts and cervical cancer. Beginning in March 2007, the Centers for Disease Control and Prevention’s Advisory Committee for Immunization Practices (ACIP) recommended routine HPV vaccination for girls 11 to 12 years of age and “catch-up” vaccination for teens and young women ages 13 to 26 years. Despite some initial safety concerns, heightened by widely publicized debate surrounding school-entry mandates, all evidence to date suggests that the HPV vaccine is effective and safe.

Using data from the 2007 California Health Interview Survey (CHIS 2007), this policy brief presents the first statewide HPV vaccination estimates among teen girls ages 13-17 and young women ages 18-26 since the ACIP recommendations were published. Knowledge of HPV, awareness of the HPV vaccine and vaccination acceptability among females ages 13-64 and parents of vaccine-eligible daughters ages 9-17 in California are also reported.
HPV Vaccination Among Young Women Ages 18-26 by Vaccine Dose, United States and California, 2007

One in Four Teen Girls in California Had Initiated the HPV Vaccine in 2007

Among teen girls in California ages 13-17, about 378,000 (26%) out of 1,468,000 reported receiving at least one dose of the vaccine. These findings are consistent with data reported from the 2007 National Immunization Survey-Teen (NIS-T 2007), showing that 25% of 13 to 17 year old females nationwide had initiated the HPV vaccine in 2007. The NIS-T data are based on parents’ reports and confirmed by provider-reported immunization records. In California, 11% of teen girls had completed the three-dose HPV vaccine series (42% of vaccine initiators), whereas only 6% of teen girls nationwide had received all three doses (24% of vaccine initiators) by the interview dates (Exhibit 1). HPV-vaccine recipients in California appear almost twice as likely to have received all three doses as teenage girls nationwide. However, the higher rates in California may be due to the fact that CHIS 2007 was in-the-field later than NIS-T 2007.

Because HPV is transmitted through sexual contact and often acquired soon after onset of sexual activity, females not yet sexually active and those with few sex partners are expected to benefit more fully from HPV vaccination. Thus, the early teen years provide a timely opportunity for vaccine intervention and HPV-related disease prevention.

HPV Vaccination Among Young Adult Women Ages 18-26 in California

Although overall vaccine effectiveness generally decreases with age and greater likelihood of HPV exposure from increasing sex partners, the majority of young adult women can still benefit from vaccination. In California, about 262,000 (12%) out of 2,273,000 females aged 18 to 26 years reported receiving at least one dose of the vaccine in 2007 and 4% had completed the vaccine series (38% of vaccine initiators). These findings provide the first reliable HPV vaccination estimates among women in this age group (Exhibit 2).

Sexually active young women ages 18-26 who have not been infected with any of the four HPV strains would receive full benefit from vaccination, while young women already infected would be protected against disease associated with the other strains. Thus, the majority of young women will derive some benefit from HPV vaccination.

The vaccine, however, does not protect against all HPV types that can lead to cervical cancer. It is critical, therefore, that even vaccinated women continue to receive regular cervical cancer screening tests, such as the Pap test.

HPV Awareness Nearly Doubles in California Since Vaccine Approval

Before the HPV vaccine was introduced, few women had heard of HPV. Since the vaccine’s approval in 2006, marketing
and media coverage has contributed to a dramatic increase in HPV awareness. In 2007, 74% of teen girls ages 13-17, 79% of young adult women ages 18-26, and 76% of older adult women ages 27-64 reported having heard of HPV.

Although HPV awareness in California was similar among age groups, there were notable differences in where respondents had heard of HPV. Television advertisements were the most commonly cited source among both young adult women ages 18-26 (61%) and older adult women ages 27-64 (53%), as well as a common source of awareness among teen girls ages 13-17 (42%). However, school was the most frequently cited source of HPV information for teen girls ages 13-17 (53%). Other frequently cited sources of HPV awareness across age groups included health care providers and family members (Exhibit 3). HPV awareness source was assessed by asking respondents where they had heard about HPV; respondents could report as many sources as applicable.

Majority of Women and Girls in California Want to be Vaccinated
Vaccine acceptability may influence an individual’s intended vaccination behavior and provides an additional indicator of future vaccine coverage. When asked if they would be interested in receiving the HPV vaccine, 76% of teen girls ages 13-17 and 60% of young adult women ages 18-26 reported an interest in getting the HPV vaccine themselves, while 57% of parents of age-eligible girls reported an interest in getting the HPV vaccine for their daughters (Exhibit 4). These findings are consistent with estimates from a representative statewide analysis showing that 75% of California parents would be likely to vaccinate their daughter before age 13, and an additional 6% would be likely to vaccinate their daughter before age 16.17

Not knowing enough about the vaccine was the main reason cited by young adult women ages 18-26 (31%) and parents of age-eligible daughters (54%) who were not interested in receiving the HPV vaccine. Other frequently cited explanations included concerns about the vaccine’s safety and questions about the vaccine’s necessity.18 While these findings are suggestive, further probing would be needed to clarify and differentiate the main reasons for not wanting to receive the vaccine. Comparable data from girls aged 13 to 17 years are not included because the teen

---

**Exhibit 3**

Source of HPV Awareness by Age Group, California 2007

<table>
<thead>
<tr>
<th>Source</th>
<th>Teen Girls Ages 13-17</th>
<th>Young Women Ages 18-26</th>
<th>Women Ages 27-64</th>
</tr>
</thead>
<tbody>
<tr>
<td>Television Ad</td>
<td>42%</td>
<td>61%</td>
<td>53%</td>
</tr>
<tr>
<td>School</td>
<td>53%</td>
<td>28%</td>
<td>8%</td>
</tr>
<tr>
<td>Health Provider</td>
<td>47%</td>
<td>53%</td>
<td>47%</td>
</tr>
<tr>
<td>Family</td>
<td>18%</td>
<td>10%</td>
<td>6%</td>
</tr>
</tbody>
</table>
version of CHIS 2007 did not include a question about why they would not want to be vaccinated (Exhibit 5).

Uncertainty and safety concerns can be expected when any new vaccine is introduced. The HPV vaccine has attracted a particularly large amount of media attention due to recent, widely publicized controversies about HPV vaccine mandates and, to a lesser extent, the relationship between childhood vaccinations and autism.19, 20 Although scientific evidence does not support a link between vaccines and autism,21 the timing of such publicity likely heightened concerns about the HPV vaccine. While no vaccine is completely without risk, the HPV vaccine has been tested in thousands of girls and young women ages 9-26 around the world with no serious side effects.22

(Continued on Page 5)
Discussion
This is the first data published on HPV vaccine use and acceptability for any state. Continued HPV vaccine monitoring in California and the nation, including girls ages 11-12 targeted for routine vaccination, would provide the opportunity to track trends in vaccine coverage, HPV-related disease incidence, HPV awareness, vaccine acceptability, and to identify populations with disproportionately lower vaccine receipt. Forthcoming analyses will explore additional factors associated with acceptability and uptake of the HPV vaccine, such as race/ethnicity, socioeconomic status and access to health care.

About CHIS/Data Source
The California Health Interview Survey is a collaboration of the UCLA Center for Health Policy Research, the California Department of Public Health, the Department of Health Care Services and the Public Health Institute. Funding for the CHIS 2007 statewide survey was provided by the California Department of Health Care Services, The California Endowment, the National Cancer Institute, the Robert Wood Johnson Foundation, the California Children and Families Commission, the California Office of the Patient Advocate, the California Department of Mental Health, the Centers for Disease Control and Prevention (CDC), Kaiser Permanente, Blue Shield of California, LA Care Health Plan, the San Diego County Health and Human Services Agency, and the California Attorney General’s Crime and Violence Prevention Center. For additional information on CHIS, visit www.chis.ucla.edu.

Author Information
David Grant, PhD, is the director of the California Health Interview Survey at the UCLA Center for Health Policy Research. Nicole Kravitz-Wirtz is an MPH student in the Department of Epidemiology at the UCLA School of Public Health and a graduate student researcher at the UCLA Center for Health Policy Research. Nancy Breen, PhD, is an economist in the Applied Research Branch of the National Cancer Institute’s Division of Cancer Control and Population Sciences and NCI CHIS project officer. Jasmin A. Tiro, PhD, is an assistant professor in the Division of Behavioral and Communication Sciences, Department of Clinical Sciences at the University of Texas Southwestern Medical Center. Jennifer Tsui, MPH, was a research associate at the UCLA Center for Health Policy Research. She is currently a doctoral student in the Department of Health Services at the UCLA School of Public Health and a graduate student researcher at the UCLA Division of Cancer Prevention and Control Research.

Acknowledgements
The authors would like to thank members of the CHIS 2007-HPV work group for their assistance developing the HPV questionnaire module. For their support and assistance with this brief, the authors would also like to thank CHIS Principal Investigator Dr. E. Richard Brown at the UCLA Center for Health Policy Research; Dr. Martin L. Brown, chief of the National Cancer Institute’s Health Services and Economics Branch, Applied Research Program, Division of Cancer Control and Population Sciences; and Dr. Y. Jenny Chia, assistant director of Statistical Support at the UCLA Center for Health Policy Research.

Suggested Citation

Notes
4 Ibid.

(Continued on Back)
9 Ibid.
10 CHIS 2007 was conducted from June 2007 through March 2008. NIS-T 2007 was conducted during the fourth quarter 2007 only.
14 Ibid.
18 Respondents reported the main reason they would not want to get the HPV vaccine. Answers were classified within the following categories: 1) Does not need vaccine; 2) Not sexually active; 3) Too expensive; 4) Too old/too young for vaccine; 5) Doctor didn’t recommend it; 6) Worried about safety of vaccine; 7) My spouse/family member is against it; 8) Don’t know enough about the vaccine; or 9) Other. Responses recorded as “does not need vaccine”, “not sexually active”, or “too old/too young for vaccine” reflect concerns related to the vaccine’s necessity and were combined into a single category, “don’t need vaccine.”